Drawing for AT ABBVIE WE SEE THE CAN IN CANCER

USPTO serial 50166158

AT ABBVIE WE SEE THE CAN IN CANCER

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
—
Law office
—

What this means

Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies. Wait for assignment and the first examiner action. Monitor TSDR monthly for status changes to 638 (assigned) or an office action.

Status 630: Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies.

Need help with AT ABBVIE WE SEE THE CAN IN CANCER?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maryam Arastu

1 N. Waukegan RoadNorth Chicago, IL 60064United States

Goods and services

ClassDescriptionStatusFirst use
035Promoting public awareness in the field of cancer researchACTIVE—
042Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Medical research services in the field of cancer; Providing medical and scientific research informationACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 16, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 16, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance